Biomarkers in epilepsy and OV329 program updates June 12, 2025 © Copyright 2025 Ovid Therapeutics Welcome Dr. Jeremy Levin Chairman & Chief Executive Officer © Copyright 2025 Ovid Therapeutics © Copyright 2025 Ovid Therapeutics 2 Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, the potential therapeutic benefits of Ovid's current or future product candidates and pipelin ...

Ovid Therapeutics (OVID) Update / Briefing June 12, 2025 09:30 AM ET Speaker0 Thank you very much for coming. Those of you here, wonderful to see you and those many of you online, I really appreciate you taking the time to spend with us today and hopefully you'll visit with us one on one. Today we're going to talk about biomarkers in epilepsy and our three twenty nine program. I'd like to really encourage you to dig in. This is an important moment for not just for Ovid, actually for the industry. Our pipeli ...

Alto Neuroscience (ANRO) 2025 Conference June 05, 2025 02:00 PM ET Speaker0 Okay, we're gonna get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies and it's my pleasure to have Amit Ekken by my side. Welcome. Speaker1 Thank you. Speaker0 I forgot to mention from Alto Neuroscience. So maybe give us spend two minutes, three minutes talking about the Alto story, what you're trying to achieve and what milestones we can expect over the next six to twelve months. You've got a lot ...

Interested in attending or participating remotely: NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr ...

Brainstorm Cell Therapeutics (BCLI) Q1 2025 Earnings Call May 19, 2025 08:30 AM ET Company Participants Joyce Lonergan - Managing DirectorChaim Lebovits - President & CEOHaro Hartounian - EVP & COOBob Dagher - EVP & Chief Medical OfficerNetta Blondheim-Shraga - SVP - Research & DevelopmentJason Mccarthy - Senior Managing Director & Head of Biotechnology Research Conference Call Participants David Bautz - Senior Analyst Operator Greetings, and welcome to the BrainStorm Cell Therapeutics Therapeutics first qu ...

Acumen Pharmaceuticals (ABOS) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Company Participants Alex Braun - VP & Head of Investor RelationsDaniel O'Connell - CEO, President & DirectorMatthew Zuga - CFO & Chief Business OfficerJim Doherty - President & Chief Development OfficerSarah Medeiros - BioPharma & Biotech Equity Research AssociateEric Siemers - Chief Medical OfficerTrung Huynh - Executive Director - Equity Research Conference Call Participants None - AnalystThomas Shrader - MD & Healthcare Analyst ...

Company Overview - Mainz BioMed is developing a novel standard for non-invasive detection of advanced adenomas (AA)[8] - The company has a disruptive, decentralized business model[9] - Mainz BioMed launched its first-generation CRC screening test, ColoAlert®, in Europe[10] - The company possesses a strong intellectual property position[12] Market Opportunity and Product - The US annual market for colorectal cancer (CRC) screening is estimated to be > $30 billion by 2032[14] - ColoAlert® is a highly efficacious, at-home, stool-based screening test for early CRC detection, combining a FIT test with PCR results of specific tumor DNA markers[15] - ColoAlert® has high accuracy with 92% specificity and 85% sensitivity[25] - In a screening population >= 45, 21% sensitivity for adenomas would reduce mortality from CRC by 47%, and 76% sensitivity would reduce mortality from CRC by 67%[21] Partnerships and Financials - Mainz BioMed entered into a Collaboration Agreement with Thermo Fisher Scientific in November 2024, with Thermo Fisher providing resources and discounts on instrumentation[17] - Mainz BioMed also entered into Agreements with Quest Diagnostics in November 2024, with Quest becoming a lab partner for the pivotal study and having a semi-exclusive distributor option right in the U S[17] - For the year ended December 31, 2024, ColoAlert® revenue was $893,991, with a gross profit of $574,883[50]

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 studyBiomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefitsPositive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patientsPresence of Circulating Tumor Cells (CTC) after patients’ initial Phase 3 treatment ...

April 28, 2025 News release BioPorto A/S to host first quarter 2025 earnings webcast for investors COPENHAGEN, DENMARK, April 28, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter 2025, CFO Niels Høy Nielsen will present financial results for Q1 2025 at a webcast for investors on May ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O???Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. ...